Pediatric Disease Registry in Essential Thrombocythaemia (ET)

Status Completed

Clinical Trial Summary

The aim of this study is to evaluate the progression of ET in children (aged 6-17years inclusive) over a period of 5 years maximum. The study will also assess how children are diagnosed, treatment options for those children with symptoms and events related to their ET and the outcomes of those treatments.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01198717
Study type	Observational
Source	Takeda
Contact
Status	Completed
Phase
Start date	September 28, 2010
Completion date	March 1, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01467661` - Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia	Phase 3
Completed	`NCT01214915` - Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia	Phase 3
Active, not recruiting	`NCT02577926` - The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia	Phase 2
Completed	`NCT03625895` - Agrylin Drug Use-Result Survey
Completed	`NCT01816256` - Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms	N/A
Completed	`NCT01352585` - Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
Completed	`NCT04243122` - Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients	Phase 2